netupitant

orally active neurokinin-1 receptor antagonist

Also Known As:

2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)propanamide; 2-(3,5-bis(trifluoromethyl)phenyl)-N-methyl-N-(4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-methylpropanamide; RO 67-3189 000; RO 673189000; RO-67-3189; RO-67-3189 000; RO-673189000; benzeneacetamide, N, alpha, alpha-trimethyl-N-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-; benzeneacetamide, N, alpha,alpha-trimethyl-N-(4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl)-3,5-bis(trifluoromethyl)-, hydrochloride (1:2); netupitant dihydrochloride; netupitant hydrochloride

Networked: 97 relevant articles (17 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Darmani, Nissar A: 8 articles (06/2021 - 04/2015)
2.	Zhong, Weixia: 8 articles (06/2021 - 04/2015)
3.	Pietra, Claudio: 7 articles (01/2018 - 08/2012)
4.	Karthaus, Meinolf: 6 articles (04/2022 - 01/2015)
5.	Aapro, Matti: 6 articles (01/2022 - 01/2015)
6.	Navari, Rudolph M: 6 articles (08/2021 - 01/2015)
7.	Bonizzoni, Erminio: 5 articles (02/2022 - 03/2020)
8.	Jordan, Karin: 5 articles (01/2022 - 02/2016)
9.	Chebolu, Seetha: 5 articles (06/2021 - 04/2015)
10.	Rizzi, Giada: 5 articles (11/2019 - 01/2017)

Related Diseases

1.	Vomiting 04/01/2015 - "On the other hand, netupitant (5mg/kg, i.p.) totally abolished vomiting during the delayed phase, and tended to suppress the mean vomit frequency during the acute phase. " 04/01/2016 - "Intracerebroventricular injection of netupitant suppressed vomiting caused by thapsigargin which suggests that the principal site of evoked emesis is the brainstem. " 01/01/2016 - "The convenience of protection afforded by the single dosing of netupitant together with palonosetron was demonstrated and also is known to provide an advantage over other therapeutic strategies to control emesis in man." 01/01/2016 - "Lower doses of netupitant (0.03-0.3 mg/kg, p.o.) dose-dependently reduced cisplatin (10 mg/kg, i.p.)-induced emesis in an acute (8 h) model, and motion-induced emesis in S. " 01/01/2014 - "Netupitant is a new, selective NK1 receptor antagonist under development for the prevention of chemotherapy-induced nausea and vomiting. "
2.	Nausea 01/01/2014 - "Netupitant is a new, selective NK1 receptor antagonist under development for the prevention of chemotherapy-induced nausea and vomiting. " 01/01/2021 - "No clinical trials have examined the effect of netupitant/palonosetron (NEPA) on chronic nausea in patients with cancer. " 01/01/2021 - "Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial." 01/01/2019 - "Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride." 08/01/2022 - "Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy."
3.	Neoplasms (Cancer) 11/01/2019 - "Fosnetupitant conversion to netupitant occurred rapidly in cancer patients. " 01/01/2019 - "Both drugs have similar intermediate-to-low systemic clearances and long half-lives (cancer patients: netupitant, 19.5-20.8 L/h and 56.0-93.8 hours; palonosetron: 7.0-11.3 L/h and 43.8-65.7 hours, respectively). " 01/01/2021 - "No clinical trials have examined the effect of netupitant/palonosetron (NEPA) on chronic nausea in patients with cancer. " 01/01/2021 - "Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial." 01/01/2014 - "Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial."
4.	Breast Neoplasms (Breast Cancer) 06/01/2017 - "Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials." 10/25/2023 - "We analyzed data from a prospective CINV prophylaxis trial of netupitant/palonestron and dexamethasone for patients receiving an anthracycline and cyclophosphamide (AC) for breast cancer (NCT0340371). " 03/19/2020 - "Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study." 04/01/2022 - "Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy."
5.	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/01/2020 - "The rationale of this multicenter, open-label and phase IIa study was to explore the efficacy of multiple doses of NEPA (netupitant/palonosetron) given as an every-other-day regimen without dexamethasone in preventing CINV in patients with relapsed-refractory aggressive non-Hodgkin's lymphoma (R/R-NHL), eligible for autologous stem cell transplantation (ASCT) and treated with MD-HD-CT. " 02/01/2022 - "Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation."

Related Drugs and Biologics

1.	Palonosetron (Aloxi)
2.	Antiemetics
3.	Aprepitant (Emend)
4.	Dexamethasone (Maxidex)
5.	Cisplatin (Platino)
6.	Serotonin (5 Hydroxytryptamine)
7.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
8.	Nifedipine (Adalat)
9.	Dopamine (Intropin)
10.	rolapitant

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stem Cell Transplantation
3.	Therapeutics
4.	Aftercare (After-Treatment)
5.	Cell Transplantation